Clinical Trial Update: Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dasatinib in combination with fludarabine and rituximab in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• DASATINIB (Dasatinib)
• Fludarabine (Fludarabine)
• Rituximab (rituximab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2017-03-20